Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
Identifieur interne : 003589 ( Main/Exploration ); précédent : 003588; suivant : 003590Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
Auteurs : RBID : pubmed:12458390English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Child, False Negative Reactions, Female, Follow-Up Studies, Glomus Tumor (diagnosis), Glomus Tumor (metabolism), Glomus Tumor (radionuclide imaging), Head and Neck Neoplasms (diagnosis), Head and Neck Neoplasms (metabolism), Head and Neck Neoplasms (radionuclide imaging), Humans, Magnetic Resonance Imaging, Male, Middle Aged, Octreotide (analogs & derivatives), Octreotide (diagnostic use), Octreotide (pharmacokinetics), Paraganglioma (diagnosis), Paraganglioma (metabolism), Paraganglioma (radionuclide imaging), Predictive Value of Tests, Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics), Receptors, Somatostatin (metabolism), Tomography, X-Ray Computed, Whole-Body Counting (methods).
- MESH :
- chemical , analogs & derivatives : Octreotide.
- diagnosis : Glomus Tumor, Head and Neck Neoplasms, Paraganglioma.
- chemical , diagnostic use : Octreotide, Radiopharmaceuticals.
- metabolism : Glomus Tumor, Head and Neck Neoplasms, Paraganglioma, Receptors, Somatostatin.
- methods : Whole-Body Counting.
- chemical , pharmacokinetics : Octreotide, Radiopharmaceuticals.
- radionuclide imaging : Glomus Tumor, Head and Neck Neoplasms, Paraganglioma.
- Adolescent, Adult, Aged, Child, False Negative Reactions, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Predictive Value of Tests, Tomography, X-Ray Computed.
Abstract
Paragangliomas or glomus tumours of the head and neck region are rare somatostatin receptor-expressing neuroendocrine tumours. Precise preoperative diagnosis is of special importance in order to adequately weigh the potential benefit of the operation against the inherent risks of the procedure. In this study, the clinical value of somatostatin receptor imaging was assessed in 19 patients who underwent somatostatin receptor scintigraphy because of known or suspected paraganglioma of the head and neck region. The results were compared with the results of computed tomography and/or magnetic resonance imaging, histology and clinical follow-up. [(111)In-DTPA- D-Phe(1)]-octreotide scintigraphy was performed 4-6 and 24 h after i.v. injection of 140-220 MBq (111)In-octreotide. Whole-body and planar images as well as single-photon emission tomography images were acquired and lesions were graded according to qualitative tracer uptake. Somatostatin receptor imaging was positive in nine patients, identifying paragangliomas for the first time in three patients and recurrent disease in six patients. In one patient, a second, previously unknown paraganglioma site was identified. Negative results were obtained in ten patients. These patients included one suffering from chronic hyperplastic otitis externa, one with granuloma tissue and an organised haematoma, one with an acoustic neuroma, one with an asymmetric internal carotid artery, two with ectasia of the bulbus venae jugularis and one with a jugular vein thrombosis. In two patients with a strong family history of paraganglioma, individual involvement could be excluded. In only one patient did somatostatin receptor imaging and magnetic resonance imaging yield false negative results in respect of recurrent paraganglioma tissue. It is concluded that somatostatin receptor scintigraphy provides important information in patients with suspected paragangliomas of the head and neck region and has a strong impact on further therapeutic management.
DOI: 10.1007/s00259-002-0939-6
PubMed: 12458390
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.</title><author><name sortKey="Schmidt, Matthias" uniqKey="Schmidt M">Matthias Schmidt</name><affiliation wicri:level="3"><nlm:affiliation>Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln, Germany. Matthias.Schmidt@uni-koeln.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Cologne</settlement></placeName></affiliation></author><author><name sortKey="Fischer, Eva" uniqKey="Fischer E">Eva Fischer</name></author><author><name sortKey="Dietlein, Markus" uniqKey="Dietlein M">Markus Dietlein</name></author><author><name sortKey="Michel, Olaf" uniqKey="Michel O">Olaf Michel</name></author><author><name sortKey="Weber, Kerstin" uniqKey="Weber K">Kerstin Weber</name></author><author><name sortKey="Moka, Detlef" uniqKey="Moka D">Detlef Moka</name></author><author><name sortKey="Stennert, Eberhard" uniqKey="Stennert E">Eberhard Stennert</name></author><author><name sortKey="Schicha, Harald" uniqKey="Schicha H">Harald Schicha</name></author></titleStmt><publicationStmt><date when="2002">2002</date><idno type="RBID">pubmed:12458390</idno><idno type="pmid">12458390</idno><idno type="doi">10.1007/s00259-002-0939-6</idno><idno type="wicri:Area/Main/Corpus">003619</idno><idno type="wicri:Area/Main/Curation">003619</idno><idno type="wicri:Area/Main/Exploration">003589</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>False Negative Reactions</term><term>Female</term><term>Follow-Up Studies</term><term>Glomus Tumor (diagnosis)</term><term>Glomus Tumor (metabolism)</term><term>Glomus Tumor (radionuclide imaging)</term><term>Head and Neck Neoplasms (diagnosis)</term><term>Head and Neck Neoplasms (metabolism)</term><term>Head and Neck Neoplasms (radionuclide imaging)</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Octreotide (pharmacokinetics)</term><term>Paraganglioma (diagnosis)</term><term>Paraganglioma (metabolism)</term><term>Paraganglioma (radionuclide imaging)</term><term>Predictive Value of Tests</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Receptors, Somatostatin (metabolism)</term><term>Tomography, X-Ray Computed</term><term>Whole-Body Counting (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Glomus Tumor</term><term>Head and Neck Neoplasms</term><term>Paraganglioma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Glomus Tumor</term><term>Head and Neck Neoplasms</term><term>Paraganglioma</term><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Whole-Body Counting</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Glomus Tumor</term><term>Head and Neck Neoplasms</term><term>Paraganglioma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>False Negative Reactions</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Paragangliomas or glomus tumours of the head and neck region are rare somatostatin receptor-expressing neuroendocrine tumours. Precise preoperative diagnosis is of special importance in order to adequately weigh the potential benefit of the operation against the inherent risks of the procedure. In this study, the clinical value of somatostatin receptor imaging was assessed in 19 patients who underwent somatostatin receptor scintigraphy because of known or suspected paraganglioma of the head and neck region. The results were compared with the results of computed tomography and/or magnetic resonance imaging, histology and clinical follow-up. [(111)In-DTPA- D-Phe(1)]-octreotide scintigraphy was performed 4-6 and 24 h after i.v. injection of 140-220 MBq (111)In-octreotide. Whole-body and planar images as well as single-photon emission tomography images were acquired and lesions were graded according to qualitative tracer uptake. Somatostatin receptor imaging was positive in nine patients, identifying paragangliomas for the first time in three patients and recurrent disease in six patients. In one patient, a second, previously unknown paraganglioma site was identified. Negative results were obtained in ten patients. These patients included one suffering from chronic hyperplastic otitis externa, one with granuloma tissue and an organised haematoma, one with an acoustic neuroma, one with an asymmetric internal carotid artery, two with ectasia of the bulbus venae jugularis and one with a jugular vein thrombosis. In two patients with a strong family history of paraganglioma, individual involvement could be excluded. In only one patient did somatostatin receptor imaging and magnetic resonance imaging yield false negative results in respect of recurrent paraganglioma tissue. It is concluded that somatostatin receptor scintigraphy provides important information in patients with suspected paragangliomas of the head and neck region and has a strong impact on further therapeutic management.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12458390</PMID><DateCreated><Year>2002</Year><Month>11</Month><Day>29</Day></DateCreated><DateCompleted><Year>2003</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1619-7070</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>12</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur. J. Nucl. Med. Mol. Imaging</ISOAbbreviation></Journal><ArticleTitle>Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.</ArticleTitle><Pagination><MedlinePgn>1571-80</MedlinePgn></Pagination><Abstract><AbstractText>Paragangliomas or glomus tumours of the head and neck region are rare somatostatin receptor-expressing neuroendocrine tumours. Precise preoperative diagnosis is of special importance in order to adequately weigh the potential benefit of the operation against the inherent risks of the procedure. In this study, the clinical value of somatostatin receptor imaging was assessed in 19 patients who underwent somatostatin receptor scintigraphy because of known or suspected paraganglioma of the head and neck region. The results were compared with the results of computed tomography and/or magnetic resonance imaging, histology and clinical follow-up. [(111)In-DTPA- D-Phe(1)]-octreotide scintigraphy was performed 4-6 and 24 h after i.v. injection of 140-220 MBq (111)In-octreotide. Whole-body and planar images as well as single-photon emission tomography images were acquired and lesions were graded according to qualitative tracer uptake. Somatostatin receptor imaging was positive in nine patients, identifying paragangliomas for the first time in three patients and recurrent disease in six patients. In one patient, a second, previously unknown paraganglioma site was identified. Negative results were obtained in ten patients. These patients included one suffering from chronic hyperplastic otitis externa, one with granuloma tissue and an organised haematoma, one with an acoustic neuroma, one with an asymmetric internal carotid artery, two with ectasia of the bulbus venae jugularis and one with a jugular vein thrombosis. In two patients with a strong family history of paraganglioma, individual involvement could be excluded. In only one patient did somatostatin receptor imaging and magnetic resonance imaging yield false negative results in respect of recurrent paraganglioma tissue. It is concluded that somatostatin receptor scintigraphy provides important information in patients with suspected paragangliomas of the head and neck region and has a strong impact on further therapeutic management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Affiliation>Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln, Germany. Matthias.Schmidt@uni-koeln.de</Affiliation></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dietlein</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Moka</LastName><ForeName>Detlef</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Stennert</LastName><ForeName>Eberhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Schicha</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Validation Studies</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">False Negative Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Glomus Tumor</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Paraganglioma</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Whole-Body Counting</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>30</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>Apr</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>Jun</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2002</Year><Month>Sep</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>30</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12458390</ArticleId><ArticleId IdType="doi">10.1007/s00259-002-0939-6</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12458390
|texte= Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12458390" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |